• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cystic fibrosis pulmonary exacerbations attributable to respiratory syncytial virus and influenza: a population-based study

tetano

Editor, Senior Moderator
Clin Infect Dis. 2017 Mar 9. doi: 10.1093/cid/cix203. [Epub ahead of print]
[h=1]Cystic fibrosis pulmonary exacerbations attributable to respiratory syncytial virus and influenza: a population-based study.[/h] Somayaji R[SUP]1[/SUP], Goss CH[SUP]2[/SUP], Khan U[SUP]3[/SUP], Neradilek M[SUP]4[/SUP], Neuzil KM[SUP]5[/SUP], Ortiz JR[SUP]6[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] [h=4]Background:[/h] Characterization of the role of respiratory viral pathogens on cystic fibrosis (CF) pulmonary disease is needed. We aimed to determine the association of influenza and respiratory syncytial virus (RSV) activity with risk of pulmonary exacerbation (PEx) in persons with CF in the United States.
[h=4]Methods:[/h] We conducted a cohort study from January 2003 - March 2009 using the CF Foundation Patient Registry merged with CDC respiratory virus surveillance data. The primary goal was to determine the association between regional influenza or RSV detections with risk of PEx requiring intravenous antibiotics or hospitalization. We analyzed outcomes by geographic region and week of event using multivariable regression models adjusted for demographic and clinical predictors of PEx stratified for children (<18 years) and adults (18 years) to calculate relative risks (RR) of PEx.
[h=4]Results:[/h] There were 21,022 individuals (52% male) in the CF patient cohort in 2003 comprised of 12,702 children and 8,320 adults. The overall incidence rate of PEx was 521.9 per 10,000 person-months. In children, a 10% increase in the proportion of surveillance tests positive for influenza or RSV were significantly associated with increased PEx risk (RR 1.02 [95% CI 1.01-1.03] ) and (RR 1.05 [95% CI 1.02-1.07],) respectively. In adults, surveillance tests positive for influenza (RR 1.02 [95% CI 1.01-1.02]) but not RSV (RR 0.99 [0.98-1.01]), had a significant association with PEx risk.
[h=4]Conclusions:[/h] Our large CF population based cohort demonstrated a significant association between PEx risk and influenza activity in children and adults and with RSV activity in children.


PMID: 28329304 DOI: 10.1093/cid/cix203
 
Back
Top Bottom